| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cartilage, Articular | 119 | 2023 | 524 | 28.950 |
Why?
|
| Knee Joint | 145 | 2023 | 797 | 24.620 |
Why?
|
| Menisci, Tibial | 69 | 2023 | 172 | 21.710 |
Why?
|
| Knee Injuries | 74 | 2022 | 223 | 18.430 |
Why?
|
| Arthroscopy | 140 | 2023 | 811 | 14.660 |
Why?
|
| Osteoarthritis, Knee | 55 | 2022 | 381 | 14.570 |
Why?
|
| Platelet-Rich Plasma | 43 | 2023 | 75 | 13.810 |
Why?
|
| Cartilage Diseases | 39 | 2023 | 83 | 13.540 |
Why?
|
| Rotator Cuff Injuries | 57 | 2023 | 280 | 12.420 |
Why?
|
| Shoulder Joint | 95 | 2023 | 572 | 11.430 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 60 | 2023 | 235 | 11.000 |
Why?
|
| Bone Transplantation | 40 | 2023 | 224 | 10.810 |
Why?
|
| Rotator Cuff | 55 | 2023 | 265 | 10.740 |
Why?
|
| Osteotomy | 28 | 2022 | 163 | 9.590 |
Why?
|
| Tibial Meniscus Injuries | 37 | 2022 | 89 | 9.590 |
Why?
|
| Allografts | 52 | 2023 | 180 | 9.570 |
Why?
|
| Humans | 534 | 2023 | 29337 | 9.160 |
Why?
|
| Anterior Cruciate Ligament Injuries | 52 | 2023 | 259 | 9.050 |
Why?
|
| Orthopedic Procedures | 45 | 2021 | 317 | 8.630 |
Why?
|
| Transplantation, Homologous | 68 | 2023 | 277 | 8.300 |
Why?
|
| Chondrocytes | 44 | 2022 | 197 | 7.400 |
Why?
|
| Cartilage | 28 | 2021 | 148 | 7.390 |
Why?
|
| Tibia | 33 | 2022 | 259 | 6.740 |
Why?
|
| Patient Reported Outcome Measures | 51 | 2023 | 379 | 6.730 |
Why?
|
| Joint Instability | 50 | 2023 | 387 | 6.650 |
Why?
|
| Adult | 209 | 2023 | 8601 | 6.390 |
Why?
|
| Treatment Outcome | 144 | 2023 | 3478 | 6.360 |
Why?
|
| Return to Sport | 21 | 2021 | 120 | 6.020 |
Why?
|
| Biological Products | 10 | 2023 | 40 | 5.970 |
Why?
|
| Femur | 36 | 2022 | 396 | 5.740 |
Why?
|
| Male | 250 | 2023 | 15621 | 5.680 |
Why?
|
| Reoperation | 58 | 2022 | 932 | 5.460 |
Why?
|
| Tendon Injuries | 26 | 2022 | 196 | 5.370 |
Why?
|
| Female | 230 | 2023 | 16197 | 5.240 |
Why?
|
| Young Adult | 93 | 2023 | 1932 | 5.150 |
Why?
|
| Middle Aged | 180 | 2022 | 9823 | 4.870 |
Why?
|
| Osteoarthritis | 26 | 2023 | 363 | 4.800 |
Why?
|
| Return to Work | 12 | 2021 | 52 | 4.770 |
Why?
|
| Shoulder | 34 | 2022 | 154 | 4.760 |
Why?
|
| Follow-Up Studies | 72 | 2023 | 1830 | 4.760 |
Why?
|
| Adolescent | 88 | 2023 | 2279 | 4.680 |
Why?
|
| Retrospective Studies | 91 | 2023 | 3273 | 4.410 |
Why?
|
| Arthroplasty, Subchondral | 12 | 2018 | 27 | 4.340 |
Why?
|
| Arthroplasty | 29 | 2023 | 136 | 4.330 |
Why?
|
| Athletic Injuries | 26 | 2020 | 178 | 4.270 |
Why?
|
| Anterior Cruciate Ligament | 41 | 2023 | 270 | 4.240 |
Why?
|
| Wound Healing | 23 | 2021 | 168 | 4.170 |
Why?
|
| Tenodesis | 22 | 2023 | 152 | 4.040 |
Why?
|
| Shoulder Injuries | 27 | 2022 | 139 | 4.010 |
Why?
|
| Orthopedics | 13 | 2023 | 127 | 3.960 |
Why?
|
| Suture Techniques | 23 | 2022 | 141 | 3.960 |
Why?
|
| Meniscus | 8 | 2023 | 18 | 3.600 |
Why?
|
| Transplantation, Autologous | 46 | 2023 | 195 | 3.580 |
Why?
|
| Osteochondritis Dissecans | 9 | 2019 | 27 | 3.540 |
Why?
|
| Patellofemoral Joint | 14 | 2023 | 52 | 3.470 |
Why?
|
| Injections, Intra-Articular | 27 | 2022 | 88 | 3.360 |
Why?
|
| Minimal Clinically Important Difference | 16 | 2022 | 106 | 3.340 |
Why?
|
| Hyaluronic Acid | 17 | 2021 | 94 | 3.300 |
Why?
|
| Pain | 26 | 2023 | 391 | 3.280 |
Why?
|
| Patient Satisfaction | 22 | 2021 | 295 | 3.200 |
Why?
|
| Magnetic Resonance Imaging | 35 | 2023 | 1221 | 3.150 |
Why?
|
| Shoulder Dislocation | 15 | 2021 | 94 | 3.040 |
Why?
|
| Suture Anchors | 15 | 2023 | 71 | 3.020 |
Why?
|
| Range of Motion, Articular | 55 | 2023 | 699 | 2.920 |
Why?
|
| Fractures, Stress | 5 | 2021 | 22 | 2.870 |
Why?
|
| Arthroplasty, Replacement, Knee | 13 | 2023 | 696 | 2.800 |
Why?
|
| Biomechanical Phenomena | 51 | 2022 | 668 | 2.760 |
Why?
|
| Sports Medicine | 7 | 2022 | 41 | 2.620 |
Why?
|
| Pain, Postoperative | 12 | 2022 | 314 | 2.430 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 13 | 2022 | 164 | 2.370 |
Why?
|
| Postoperative Complications | 24 | 2021 | 957 | 2.320 |
Why?
|
| Recovery of Function | 23 | 2020 | 290 | 2.300 |
Why?
|
| Pain Measurement | 27 | 2022 | 462 | 2.290 |
Why?
|
| Joint Diseases | 9 | 2020 | 110 | 2.230 |
Why?
|
| Tendons | 20 | 2023 | 218 | 2.210 |
Why?
|
| Meniscectomy | 11 | 2022 | 22 | 2.180 |
Why?
|
| Cadaver | 44 | 2022 | 359 | 2.030 |
Why?
|
| Humeral Head | 7 | 2021 | 26 | 2.000 |
Why?
|
| Anesthetics, Local | 5 | 2019 | 91 | 1.990 |
Why?
|
| Chondrogenesis | 7 | 2020 | 27 | 1.890 |
Why?
|
| Ligaments, Articular | 14 | 2022 | 104 | 1.870 |
Why?
|
| Prospective Studies | 36 | 2023 | 1811 | 1.850 |
Why?
|
| Aged | 78 | 2021 | 9448 | 1.850 |
Why?
|
| Graft Survival | 11 | 2020 | 98 | 1.770 |
Why?
|
| Debridement | 17 | 2018 | 100 | 1.750 |
Why?
|
| Cohort Studies | 36 | 2023 | 1939 | 1.750 |
Why?
|
| Radiography | 24 | 2020 | 678 | 1.690 |
Why?
|
| Postoperative Period | 22 | 2022 | 288 | 1.650 |
Why?
|
| Tendinopathy | 10 | 2021 | 60 | 1.570 |
Why?
|
| Scapula | 11 | 2020 | 79 | 1.570 |
Why?
|
| Quality of Life | 20 | 2022 | 662 | 1.550 |
Why?
|
| Bone Marrow | 9 | 2023 | 73 | 1.550 |
Why?
|
| Sutures | 5 | 2021 | 41 | 1.530 |
Why?
|
| Growth Plate | 2 | 2020 | 23 | 1.500 |
Why?
|
| Bone Screws | 8 | 2023 | 181 | 1.490 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 324 | 1.470 |
Why?
|
| Psychometrics | 4 | 2021 | 262 | 1.410 |
Why?
|
| Stem Cell Transplantation | 4 | 2020 | 40 | 1.400 |
Why?
|
| Physical Examination | 15 | 2019 | 117 | 1.390 |
Why?
|
| Animals | 41 | 2022 | 4552 | 1.390 |
Why?
|
| Tissue Engineering | 6 | 2012 | 36 | 1.370 |
Why?
|
| Absorbable Implants | 6 | 2014 | 24 | 1.350 |
Why?
|
| Activities of Daily Living | 12 | 2022 | 501 | 1.330 |
Why?
|
| Athletes | 11 | 2022 | 76 | 1.330 |
Why?
|
| Research Design | 5 | 2020 | 212 | 1.330 |
Why?
|
| Treatment Failure | 15 | 2020 | 159 | 1.310 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2021 | 100 | 1.260 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2020 | 770 | 1.260 |
Why?
|
| United States | 30 | 2021 | 2333 | 1.250 |
Why?
|
| Intra-Articular Fractures | 5 | 2020 | 16 | 1.230 |
Why?
|
| Muscle, Skeletal | 16 | 2022 | 349 | 1.220 |
Why?
|
| Time Factors | 25 | 2021 | 1616 | 1.220 |
Why?
|
| Bone Malalignment | 3 | 2016 | 20 | 1.200 |
Why?
|
| Upper Extremity | 9 | 2021 | 49 | 1.180 |
Why?
|
| Autografts | 9 | 2023 | 32 | 1.160 |
Why?
|
| Quality Improvement | 3 | 2019 | 158 | 1.160 |
Why?
|
| Patient Selection | 10 | 2020 | 232 | 1.140 |
Why?
|
| Tissue Transplantation | 6 | 2016 | 19 | 1.120 |
Why?
|
| Viscosupplementation | 4 | 2020 | 8 | 1.100 |
Why?
|
| Postoperative Care | 11 | 2020 | 127 | 1.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 194 | 1.090 |
Why?
|
| Patella | 11 | 2022 | 81 | 1.090 |
Why?
|
| Viscosupplements | 4 | 2020 | 11 | 1.080 |
Why?
|
| Imaging, Three-Dimensional | 14 | 2020 | 222 | 1.080 |
Why?
|
| Baseball | 9 | 2017 | 105 | 1.060 |
Why?
|
| Hyaline Cartilage | 6 | 2020 | 15 | 1.040 |
Why?
|
| Bupivacaine | 3 | 2012 | 54 | 1.030 |
Why?
|
| Arthralgia | 11 | 2020 | 121 | 1.020 |
Why?
|
| Surgeons | 3 | 2021 | 76 | 1.010 |
Why?
|
| Bone and Bones | 5 | 2018 | 119 | 0.990 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 788 | 0.980 |
Why?
|
| Surveys and Questionnaires | 19 | 2020 | 1184 | 0.970 |
Why?
|
| Preoperative Period | 6 | 2020 | 65 | 0.960 |
Why?
|
| Recurrence | 16 | 2021 | 350 | 0.960 |
Why?
|
| Musculoskeletal Diseases | 2 | 2023 | 41 | 0.940 |
Why?
|
| X-Ray Microtomography | 4 | 2021 | 72 | 0.940 |
Why?
|
| Computer Simulation | 10 | 2022 | 218 | 0.940 |
Why?
|
| Fibrin Tissue Adhesive | 4 | 2022 | 8 | 0.930 |
Why?
|
| Glenoid Cavity | 5 | 2015 | 34 | 0.930 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2013 | 59 | 0.920 |
Why?
|
| Hemiarthroplasty | 4 | 2022 | 31 | 0.910 |
Why?
|
| Writing | 1 | 2023 | 20 | 0.900 |
Why?
|
| Orthopedic Surgeons | 3 | 2021 | 27 | 0.900 |
Why?
|
| Ossification, Heterotopic | 2 | 2022 | 42 | 0.890 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 22 | 0.890 |
Why?
|
| Humerus | 9 | 2019 | 98 | 0.870 |
Why?
|
| Extracellular Matrix | 2 | 2021 | 74 | 0.850 |
Why?
|
| Elbow Joint | 7 | 2015 | 131 | 0.850 |
Why?
|
| Acromion | 6 | 2018 | 26 | 0.850 |
Why?
|
| Venous Thrombosis | 2 | 2017 | 42 | 0.840 |
Why?
|
| Patellar Ligament | 8 | 2023 | 52 | 0.830 |
Why?
|
| Arthritis | 5 | 2016 | 107 | 0.820 |
Why?
|
| Child | 13 | 2022 | 1346 | 0.810 |
Why?
|
| Incidence | 11 | 2019 | 756 | 0.790 |
Why?
|
| Arm | 9 | 2022 | 78 | 0.790 |
Why?
|
| Surgical Wound | 1 | 2021 | 11 | 0.790 |
Why?
|
| Databases, Factual | 9 | 2019 | 330 | 0.770 |
Why?
|
| Double-Blind Method | 7 | 2022 | 503 | 0.770 |
Why?
|
| Amnion | 2 | 2020 | 5 | 0.750 |
Why?
|
| Cell Separation | 1 | 2020 | 42 | 0.740 |
Why?
|
| Anesthesia, Dental | 1 | 2019 | 1 | 0.740 |
Why?
|
| Carticaine | 1 | 2019 | 1 | 0.740 |
Why?
|
| Stem Cells | 1 | 2020 | 46 | 0.730 |
Why?
|
| Exercise Therapy | 4 | 2017 | 112 | 0.730 |
Why?
|
| Genu Varum | 1 | 2019 | 3 | 0.720 |
Why?
|
| Basketball | 3 | 2016 | 10 | 0.720 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 59 | 0.720 |
Why?
|
| Rupture | 14 | 2021 | 115 | 0.720 |
Why?
|
| Risk Factors | 21 | 2020 | 2443 | 0.710 |
Why?
|
| Cumulative Trauma Disorders | 3 | 2017 | 16 | 0.700 |
Why?
|
| Leukocytes | 3 | 2016 | 43 | 0.700 |
Why?
|
| Muscle Strength | 5 | 2017 | 127 | 0.690 |
Why?
|
| Catheter Ablation | 4 | 2008 | 78 | 0.690 |
Why?
|
| Shoulder Pain | 5 | 2017 | 55 | 0.690 |
Why?
|
| Age Factors | 15 | 2021 | 843 | 0.680 |
Why?
|
| Nerve Block | 1 | 2019 | 62 | 0.670 |
Why?
|
| Patellofemoral Pain Syndrome | 2 | 2017 | 3 | 0.660 |
Why?
|
| Patient Outcome Assessment | 5 | 2018 | 43 | 0.660 |
Why?
|
| Proteoglycans | 10 | 2022 | 337 | 0.650 |
Why?
|
| Serum Albumin, Human | 1 | 2017 | 1 | 0.640 |
Why?
|
| Stifle | 1 | 2018 | 11 | 0.640 |
Why?
|
| Football | 5 | 2018 | 36 | 0.640 |
Why?
|
| Evidence-Based Medicine | 8 | 2020 | 208 | 0.630 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2015 | 132 | 0.600 |
Why?
|
| Regeneration | 3 | 2011 | 27 | 0.600 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2022 | 340 | 0.600 |
Why?
|
| Patient Preference | 1 | 2017 | 33 | 0.600 |
Why?
|
| Bone Morphogenetic Proteins | 4 | 2011 | 102 | 0.600 |
Why?
|
| Health Literacy | 1 | 2018 | 102 | 0.590 |
Why?
|
| Soccer | 3 | 2018 | 19 | 0.590 |
Why?
|
| Prognosis | 10 | 2019 | 840 | 0.590 |
Why?
|
| Synovial Fluid | 2 | 2017 | 123 | 0.590 |
Why?
|
| Workers' Compensation | 6 | 2021 | 59 | 0.590 |
Why?
|
| Physical Therapy Modalities | 6 | 2019 | 80 | 0.590 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 36 | 0.580 |
Why?
|
| Stress, Mechanical | 9 | 2020 | 166 | 0.580 |
Why?
|
| Second-Look Surgery | 5 | 2020 | 12 | 0.580 |
Why?
|
| Sodium Chloride | 1 | 2016 | 37 | 0.580 |
Why?
|
| Soft Tissue Injuries | 2 | 2016 | 17 | 0.570 |
Why?
|
| Bone-Patellar Tendon-Bone Grafting | 8 | 2023 | 44 | 0.570 |
Why?
|
| Hamstring Muscles | 1 | 2016 | 14 | 0.560 |
Why?
|
| Lysholm Knee Score | 4 | 2021 | 6 | 0.560 |
Why?
|
| Cytokines | 7 | 2018 | 347 | 0.560 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 162 | 0.560 |
Why?
|
| Time-to-Treatment | 2 | 2015 | 32 | 0.550 |
Why?
|
| Weight-Bearing | 9 | 2018 | 164 | 0.550 |
Why?
|
| Prostheses and Implants | 5 | 2008 | 166 | 0.550 |
Why?
|
| Tenotomy | 1 | 2015 | 16 | 0.540 |
Why?
|
| Quadriceps Muscle | 4 | 2020 | 27 | 0.540 |
Why?
|
| Tissue Donors | 3 | 2019 | 74 | 0.540 |
Why?
|
| Tissue Adhesives | 2 | 2019 | 8 | 0.530 |
Why?
|
| Multivariate Analysis | 10 | 2021 | 324 | 0.530 |
Why?
|
| Lidocaine | 2 | 2019 | 40 | 0.520 |
Why?
|
| Sterilization | 2 | 2014 | 10 | 0.520 |
Why?
|
| Knee Prosthesis | 2 | 2016 | 248 | 0.520 |
Why?
|
| Analgesics, Opioid | 4 | 2022 | 215 | 0.510 |
Why?
|
| Ontario | 3 | 2020 | 17 | 0.500 |
Why?
|
| Cell Survival | 10 | 2020 | 169 | 0.500 |
Why?
|
| Aged, 80 and over | 20 | 2018 | 4851 | 0.500 |
Why?
|
| Serial Publications | 1 | 2014 | 1 | 0.500 |
Why?
|
| Transforming Growth Factor beta | 3 | 2008 | 123 | 0.500 |
Why?
|
| Collateral Ligaments | 2 | 2013 | 25 | 0.490 |
Why?
|
| Osteochondritis | 2 | 2011 | 4 | 0.490 |
Why?
|
| Cryopreservation | 2 | 2018 | 24 | 0.490 |
Why?
|
| Cost-Benefit Analysis | 5 | 2022 | 144 | 0.480 |
Why?
|
| Case-Control Studies | 9 | 2020 | 638 | 0.470 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2014 | 52 | 0.470 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 724 | 0.470 |
Why?
|
| Athletic Performance | 4 | 2020 | 18 | 0.470 |
Why?
|
| Chlorhexidine | 1 | 2014 | 61 | 0.470 |
Why?
|
| Gymnastics | 2 | 2010 | 4 | 0.460 |
Why?
|
| Rabbits | 7 | 2015 | 280 | 0.450 |
Why?
|
| Sex Factors | 6 | 2019 | 496 | 0.440 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 241 | 0.430 |
Why?
|
| Random Allocation | 9 | 2019 | 146 | 0.430 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2011 | 54 | 0.420 |
Why?
|
| Cells, Cultured | 5 | 2020 | 676 | 0.400 |
Why?
|
| Clinical Competence | 3 | 2019 | 230 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 107 | 0.390 |
Why?
|
| Pilot Projects | 5 | 2019 | 394 | 0.380 |
Why?
|
| Therapeutic Irrigation | 5 | 2013 | 66 | 0.380 |
Why?
|
| Algorithms | 6 | 2020 | 400 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2014 | 100 | 0.380 |
Why?
|
| Rotation | 12 | 2018 | 142 | 0.380 |
Why?
|
| Ulna | 1 | 2010 | 29 | 0.380 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2005 | 17 | 0.370 |
Why?
|
| Contraindications, Procedure | 2 | 2020 | 2 | 0.370 |
Why?
|
| Fractures, Cartilage | 1 | 2010 | 4 | 0.370 |
Why?
|
| Biocompatible Materials | 6 | 2016 | 114 | 0.370 |
Why?
|
| Arthroplasty, Replacement | 5 | 2014 | 147 | 0.370 |
Why?
|
| Tendon Transfer | 3 | 2015 | 23 | 0.370 |
Why?
|
| Models, Animal | 6 | 2015 | 126 | 0.360 |
Why?
|
| Cattle | 7 | 2019 | 217 | 0.360 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2010 | 300 | 0.350 |
Why?
|
| Fibrocartilage | 2 | 2015 | 9 | 0.350 |
Why?
|
| Methylprednisolone | 1 | 2009 | 24 | 0.340 |
Why?
|
| Demography | 2 | 2019 | 77 | 0.340 |
Why?
|
| Child, Preschool | 3 | 2021 | 642 | 0.340 |
Why?
|
| Hemostasis, Surgical | 2 | 2006 | 15 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 162 | 0.340 |
Why?
|
| Survivorship | 3 | 2023 | 17 | 0.340 |
Why?
|
| Brachial Plexus | 1 | 2008 | 4 | 0.330 |
Why?
|
| Rats | 5 | 2020 | 854 | 0.330 |
Why?
|
| Wounds and Injuries | 4 | 2019 | 44 | 0.330 |
Why?
|
| Decompression, Surgical | 2 | 2012 | 141 | 0.330 |
Why?
|
| Lower Extremity Deformities, Congenital | 1 | 2008 | 1 | 0.320 |
Why?
|
| Simulation Training | 2 | 2019 | 34 | 0.320 |
Why?
|
| Freezing | 1 | 2008 | 14 | 0.320 |
Why?
|
| Conflict of Interest | 2 | 2019 | 18 | 0.320 |
Why?
|
| Patient Positioning | 2 | 2020 | 38 | 0.320 |
Why?
|
| Graft Rejection | 5 | 2014 | 76 | 0.310 |
Why?
|
| Patient Care Planning | 2 | 2005 | 56 | 0.310 |
Why?
|
| Lower Extremity | 2 | 2018 | 38 | 0.310 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2007 | 3 | 0.310 |
Why?
|
| Physician Incentive Plans | 1 | 2007 | 2 | 0.310 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2007 | 11 | 0.310 |
Why?
|
| Tissue Scaffolds | 3 | 2015 | 22 | 0.300 |
Why?
|
| Patellar Dislocation | 2 | 2019 | 21 | 0.300 |
Why?
|
| Electric Stimulation | 1 | 2007 | 83 | 0.300 |
Why?
|
| Decision Making | 2 | 2011 | 220 | 0.300 |
Why?
|
| Information Systems | 3 | 2021 | 20 | 0.300 |
Why?
|
| Prosthesis Failure | 2 | 2014 | 556 | 0.300 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1113 | 0.290 |
Why?
|
| Preoperative Care | 4 | 2020 | 135 | 0.290 |
Why?
|
| Bone Resorption | 2 | 2019 | 104 | 0.290 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2006 | 26 | 0.290 |
Why?
|
| Depression | 2 | 2021 | 465 | 0.290 |
Why?
|
| Physicians | 3 | 2019 | 115 | 0.290 |
Why?
|
| Models, Anatomic | 3 | 2013 | 52 | 0.280 |
Why?
|
| Visual Analog Scale | 3 | 2020 | 49 | 0.280 |
Why?
|
| Patient Readmission | 2 | 2018 | 123 | 0.280 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 142 | 0.280 |
Why?
|
| Ankle Joint | 2 | 2019 | 39 | 0.280 |
Why?
|
| Foreign-Body Migration | 1 | 2006 | 25 | 0.280 |
Why?
|
| Organ Preservation | 1 | 2005 | 6 | 0.270 |
Why?
|
| Pain Management | 1 | 2007 | 143 | 0.270 |
Why?
|
| Tennis Elbow | 2 | 2019 | 13 | 0.270 |
Why?
|
| Bursa, Synovial | 1 | 2005 | 8 | 0.270 |
Why?
|
| Electrocoagulation | 1 | 2005 | 16 | 0.260 |
Why?
|
| Burns | 1 | 2005 | 21 | 0.260 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 553 | 0.260 |
Why?
|
| Cell Transplantation | 3 | 2010 | 29 | 0.260 |
Why?
|
| Materials Testing | 4 | 2017 | 137 | 0.260 |
Why?
|
| Connective Tissue | 3 | 2013 | 25 | 0.260 |
Why?
|
| Collagen Type III | 3 | 2015 | 13 | 0.260 |
Why?
|
| Collagen Type I | 3 | 2015 | 18 | 0.260 |
Why?
|
| Disease Progression | 3 | 2016 | 787 | 0.250 |
Why?
|
| Contraindications | 2 | 2016 | 41 | 0.250 |
Why?
|
| Shoulder Impingement Syndrome | 3 | 2014 | 11 | 0.250 |
Why?
|
| Equipment Design | 5 | 2017 | 185 | 0.250 |
Why?
|
| Analysis of Variance | 6 | 2011 | 321 | 0.250 |
Why?
|
| Posterior Cruciate Ligament | 3 | 2020 | 23 | 0.250 |
Why?
|
| Single-Blind Method | 4 | 2008 | 118 | 0.250 |
Why?
|
| Health Care Surveys | 2 | 2014 | 67 | 0.240 |
Why?
|
| Chondromalacia Patellae | 3 | 2009 | 4 | 0.240 |
Why?
|
| Rheumatic Diseases | 1 | 2005 | 56 | 0.240 |
Why?
|
| Biomarkers | 2 | 2020 | 689 | 0.240 |
Why?
|
| Pectoralis Muscles | 2 | 2015 | 18 | 0.240 |
Why?
|
| Prevalence | 4 | 2015 | 487 | 0.230 |
Why?
|
| Pressure | 6 | 2015 | 59 | 0.230 |
Why?
|
| Risk Assessment | 6 | 2017 | 679 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 7 | 2020 | 41 | 0.230 |
Why?
|
| Casts, Surgical | 1 | 2003 | 8 | 0.230 |
Why?
|
| Occlusive Dressings | 1 | 2003 | 2 | 0.230 |
Why?
|
| Survival Rate | 3 | 2021 | 349 | 0.230 |
Why?
|
| Lacerations | 2 | 2013 | 16 | 0.230 |
Why?
|
| Osteolysis | 2 | 2016 | 149 | 0.230 |
Why?
|
| Regression Analysis | 4 | 2014 | 298 | 0.230 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 97 | 0.230 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2020 | 33 | 0.230 |
Why?
|
| Patient Care | 1 | 2023 | 34 | 0.220 |
Why?
|
| Health Surveys | 2 | 2021 | 96 | 0.220 |
Why?
|
| Aggrecans | 3 | 2019 | 146 | 0.220 |
Why?
|
| Knee | 4 | 2020 | 44 | 0.220 |
Why?
|
| Joint Dislocations | 4 | 2019 | 57 | 0.220 |
Why?
|
| Publishing | 1 | 2023 | 38 | 0.220 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 29 | 0.220 |
Why?
|
| Synovial Membrane | 3 | 2013 | 81 | 0.210 |
Why?
|
| Retinal Degeneration | 1 | 2021 | 4 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 333 | 0.210 |
Why?
|
| Health Status Indicators | 3 | 2012 | 78 | 0.210 |
Why?
|
| Creatine | 1 | 2021 | 4 | 0.210 |
Why?
|
| Placenta | 1 | 2021 | 13 | 0.210 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 150 | 0.210 |
Why?
|
| Electromyography | 3 | 2016 | 78 | 0.200 |
Why?
|
| Collagen | 4 | 2013 | 102 | 0.200 |
Why?
|
| Pregnancy | 2 | 2021 | 403 | 0.200 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 2016 | 74 | 0.200 |
Why?
|
| Private Practice | 2 | 2014 | 6 | 0.200 |
Why?
|
| Amniotic Fluid | 1 | 2020 | 6 | 0.200 |
Why?
|
| Radio Waves | 3 | 2008 | 8 | 0.200 |
Why?
|
| Polymers | 4 | 2019 | 42 | 0.200 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2021 | 13 | 0.200 |
Why?
|
| Body Mass Index | 4 | 2020 | 428 | 0.200 |
Why?
|
| Dermis | 1 | 2020 | 5 | 0.200 |
Why?
|
| Internship and Residency | 3 | 2021 | 211 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 79 | 0.190 |
Why?
|
| Posterior Cruciate Ligament Reconstruction | 1 | 2020 | 5 | 0.190 |
Why?
|
| Practice Management, Medical | 1 | 2020 | 3 | 0.190 |
Why?
|
| Perioperative Period | 1 | 2020 | 12 | 0.190 |
Why?
|
| Models, Biological | 3 | 2019 | 343 | 0.190 |
Why?
|
| Polycarboxylate Cement | 3 | 2010 | 8 | 0.190 |
Why?
|
| Ketones | 3 | 2019 | 18 | 0.190 |
Why?
|
| Compressive Strength | 4 | 2008 | 28 | 0.190 |
Why?
|
| Benzophenones | 3 | 2019 | 27 | 0.190 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 90 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 959 | 0.190 |
Why?
|
| Research | 1 | 2020 | 54 | 0.190 |
Why?
|
| Movement | 3 | 2018 | 143 | 0.190 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 21 | 0.190 |
Why?
|
| Molar | 1 | 2019 | 1 | 0.190 |
Why?
|
| Mandibular Nerve | 1 | 2019 | 4 | 0.180 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 20 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 21 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 49 | 0.180 |
Why?
|
| Bone Diseases | 2 | 2019 | 24 | 0.180 |
Why?
|
| ROC Curve | 4 | 2020 | 138 | 0.180 |
Why?
|
| Self Report | 3 | 2019 | 218 | 0.180 |
Why?
|
| Temperature | 2 | 2018 | 76 | 0.180 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 55 | 0.180 |
Why?
|
| Chronic Disease | 3 | 2012 | 495 | 0.180 |
Why?
|
| Ankle | 1 | 2019 | 17 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2020 | 227 | 0.180 |
Why?
|
| Consensus | 1 | 2019 | 105 | 0.180 |
Why?
|
| Infant | 1 | 2021 | 531 | 0.170 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 153 | 0.170 |
Why?
|
| Aging | 4 | 2022 | 1593 | 0.170 |
Why?
|
| Fracture Fixation, Internal | 1 | 2019 | 71 | 0.170 |
Why?
|
| Polyurethanes | 2 | 2010 | 9 | 0.170 |
Why?
|
| Probability | 3 | 2007 | 94 | 0.170 |
Why?
|
| Patients | 1 | 2019 | 31 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 138 | 0.170 |
Why?
|
| Fluoroscopy | 2 | 2011 | 52 | 0.170 |
Why?
|
| Research Subjects | 1 | 2018 | 13 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.170 |
Why?
|
| Mental Health | 1 | 2020 | 105 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 152 | 0.170 |
Why?
|
| Rotator Cuff Tear Arthropathy | 1 | 2018 | 12 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2020 | 285 | 0.170 |
Why?
|
| Thyroidectomy | 1 | 1998 | 11 | 0.170 |
Why?
|
| Propionibacterium acnes | 1 | 2018 | 8 | 0.170 |
Why?
|
| Carcinoma, Papillary | 1 | 1998 | 20 | 0.170 |
Why?
|
| Doxycycline | 1 | 2018 | 22 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 11 | 0.160 |
Why?
|
| Horses | 2 | 2016 | 19 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.160 |
Why?
|
| Surgery Department, Hospital | 1 | 1998 | 5 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 89 | 0.160 |
Why?
|
| Prospective Payment System | 1 | 1998 | 4 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 81 | 0.160 |
Why?
|
| Diagnosis-Related Groups | 1 | 1998 | 10 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 1998 | 37 | 0.160 |
Why?
|
| Durapatite | 1 | 1997 | 11 | 0.160 |
Why?
|
| Molecular Weight | 1 | 2017 | 45 | 0.160 |
Why?
|
| Medical Records | 1 | 1998 | 29 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 236 | 0.160 |
Why?
|
| Medical Staff, Hospital | 1 | 1998 | 19 | 0.160 |
Why?
|
| Carboplatin | 1 | 1997 | 49 | 0.160 |
Why?
|
| Humeral Fractures | 1 | 2017 | 22 | 0.160 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1997 | 6 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2015 | 127 | 0.160 |
Why?
|
| Paclitaxel | 1 | 1997 | 74 | 0.160 |
Why?
|
| Pneumonia | 1 | 2018 | 67 | 0.160 |
Why?
|
| Pyridones | 1 | 2017 | 13 | 0.160 |
Why?
|
| Body Height | 3 | 2015 | 33 | 0.160 |
Why?
|
| Fever | 1 | 2017 | 40 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1997 | 24 | 0.150 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 45 | 0.150 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2012 | 46 | 0.150 |
Why?
|
| Osteoporosis | 1 | 2018 | 80 | 0.150 |
Why?
|
| Observer Variation | 3 | 2012 | 118 | 0.150 |
Why?
|
| Gait | 2 | 2016 | 404 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2017 | 66 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 391 | 0.150 |
Why?
|
| Achilles Tendon | 2 | 2014 | 18 | 0.150 |
Why?
|
| Disclosure | 1 | 2016 | 16 | 0.150 |
Why?
|
| Tensile Strength | 3 | 2019 | 29 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 1997 | 133 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2017 | 164 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2016 | 14 | 0.140 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2016 | 24 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 178 | 0.140 |
Why?
|
| Disability Evaluation | 3 | 2020 | 327 | 0.140 |
Why?
|
| Deltoid Muscle | 1 | 2015 | 6 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 290 | 0.140 |
Why?
|
| Mice | 6 | 2021 | 1607 | 0.140 |
Why?
|
| Network Meta-Analysis | 3 | 2021 | 22 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 451 | 0.140 |
Why?
|
| Capsaicin | 1 | 2015 | 11 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 2 | 2010 | 34 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 214 | 0.130 |
Why?
|
| Arthrography | 2 | 2015 | 26 | 0.130 |
Why?
|
| Thoracic Nerves | 1 | 2015 | 3 | 0.130 |
Why?
|
| Mononeuropathies | 1 | 2015 | 3 | 0.130 |
Why?
|
| Paralysis | 1 | 2015 | 19 | 0.130 |
Why?
|
| Bone-Patellar Tendon-Bone Grafts | 1 | 2014 | 4 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 2 | 2009 | 31 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 402 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2016 | 190 | 0.130 |
Why?
|
| Palliative Care | 2 | 2007 | 145 | 0.130 |
Why?
|
| Epinephrine | 2 | 2006 | 35 | 0.130 |
Why?
|
| Knee Dislocation | 2 | 2005 | 7 | 0.130 |
Why?
|
| Musculoskeletal System | 1 | 2014 | 6 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 24 | 0.130 |
Why?
|
| Ilium | 1 | 2014 | 31 | 0.120 |
Why?
|
| New England | 1 | 2014 | 2 | 0.120 |
Why?
|
| Elementary Particles | 1 | 2014 | 5 | 0.120 |
Why?
|
| Quantum Theory | 1 | 2014 | 6 | 0.120 |
Why?
|
| Acupuncture | 1 | 2013 | 2 | 0.120 |
Why?
|
| Guided Tissue Regeneration | 1 | 2013 | 10 | 0.120 |
Why?
|
| Placebos | 1 | 2014 | 77 | 0.120 |
Why?
|
| Elbow | 3 | 2021 | 42 | 0.120 |
Why?
|
| Models, Educational | 1 | 2013 | 36 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 25 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2014 | 67 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2014 | 91 | 0.120 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 12 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2014 | 96 | 0.120 |
Why?
|
| Hospitalization | 1 | 2016 | 317 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 78 | 0.110 |
Why?
|
| Acromioclavicular Joint | 1 | 2013 | 18 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1442 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2019 | 201 | 0.110 |
Why?
|
| ADAM Proteins | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cell Death | 5 | 2007 | 61 | 0.110 |
Why?
|
| Reference Values | 3 | 2010 | 227 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2020 | 57 | 0.110 |
Why?
|
| Stilbenes | 1 | 2012 | 4 | 0.110 |
Why?
|
| Polyphenols | 1 | 2012 | 5 | 0.110 |
Why?
|
| Osteophyte | 2 | 2012 | 6 | 0.110 |
Why?
|
| Chondrosarcoma | 1 | 2012 | 30 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2012 | 5 | 0.110 |
Why?
|
| Microscopy, Confocal | 4 | 2007 | 116 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 22 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2012 | 62 | 0.110 |
Why?
|
| Joint Prosthesis | 1 | 2013 | 83 | 0.110 |
Why?
|
| Equipment Failure | 2 | 2017 | 51 | 0.110 |
Why?
|
| Goats | 2 | 2009 | 10 | 0.110 |
Why?
|
| Arm Injuries | 1 | 2012 | 11 | 0.110 |
Why?
|
| Transforming Growth Factors | 1 | 2011 | 2 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2011 | 4 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2011 | 7 | 0.100 |
Why?
|
| Braces | 2 | 2016 | 26 | 0.100 |
Why?
|
| Ceramics | 1 | 2011 | 23 | 0.100 |
Why?
|
| Acute Disease | 2 | 2010 | 226 | 0.100 |
Why?
|
| Osseointegration | 1 | 2012 | 76 | 0.100 |
Why?
|
| Synovitis | 1 | 2011 | 22 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 101 | 0.100 |
Why?
|
| Age Distribution | 3 | 2016 | 94 | 0.100 |
Why?
|
| Joint Capsule Release | 1 | 2011 | 6 | 0.100 |
Why?
|
| Epiphyses | 2 | 2020 | 13 | 0.100 |
Why?
|
| Work Capacity Evaluation | 1 | 2010 | 8 | 0.100 |
Why?
|
| Hot Temperature | 2 | 2008 | 23 | 0.090 |
Why?
|
| Resistance Training | 1 | 2010 | 8 | 0.090 |
Why?
|
| Dissection | 1 | 2010 | 27 | 0.090 |
Why?
|
| Machine Learning | 2 | 2021 | 54 | 0.090 |
Why?
|
| Comorbidity | 2 | 2018 | 498 | 0.090 |
Why?
|
| Software | 2 | 2021 | 72 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 63 | 0.090 |
Why?
|
| Documentation | 2 | 2022 | 31 | 0.090 |
Why?
|
| Transplants | 1 | 2009 | 11 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2015 | 31 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2009 | 19 | 0.090 |
Why?
|
| Prosthesis Fitting | 1 | 2009 | 22 | 0.090 |
Why?
|
| Organ Size | 1 | 2009 | 107 | 0.090 |
Why?
|
| Fallopian Tube Diseases | 1 | 2009 | 1 | 0.090 |
Why?
|
| Infertility, Female | 1 | 2009 | 19 | 0.090 |
Why?
|
| Risk | 2 | 2020 | 217 | 0.090 |
Why?
|
| Anesthetics | 1 | 2009 | 25 | 0.090 |
Why?
|
| Asepsis | 1 | 2008 | 2 | 0.090 |
Why?
|
| Body Weight | 1 | 2009 | 133 | 0.090 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 1997 | 863 | 0.080 |
Why?
|
| Dogs | 2 | 2008 | 253 | 0.080 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2008 | 15 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2009 | 132 | 0.080 |
Why?
|
| Substance P | 1 | 2008 | 18 | 0.080 |
Why?
|
| Axons | 1 | 2008 | 38 | 0.080 |
Why?
|
| Torque | 3 | 2017 | 27 | 0.080 |
Why?
|
| Elasticity | 1 | 2008 | 39 | 0.080 |
Why?
|
| Transplantation | 1 | 2008 | 5 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2008 | 26 | 0.080 |
Why?
|
| Horse Diseases | 1 | 2008 | 4 | 0.080 |
Why?
|
| Logistic Models | 2 | 2020 | 407 | 0.080 |
Why?
|
| Egypt | 1 | 2007 | 3 | 0.080 |
Why?
|
| Smoking | 3 | 2018 | 194 | 0.080 |
Why?
|
| Management Information Systems | 1 | 2007 | 3 | 0.080 |
Why?
|
| Hip Joint | 1 | 2011 | 367 | 0.080 |
Why?
|
| Internal Fixators | 1 | 2007 | 54 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 23 | 0.070 |
Why?
|
| Tissue Preservation | 1 | 2006 | 6 | 0.070 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2006 | 6 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 13 | 0.070 |
Why?
|
| Ultrasonic Therapy | 1 | 2006 | 20 | 0.070 |
Why?
|
| Forecasting | 2 | 2005 | 117 | 0.070 |
Why?
|
| Collagen Type II | 2 | 2019 | 31 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2006 | 82 | 0.070 |
Why?
|
| Mechanics | 1 | 2006 | 4 | 0.070 |
Why?
|
| Muscle Weakness | 1 | 2006 | 32 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 34 | 0.070 |
Why?
|
| Arthroscopes | 2 | 2007 | 9 | 0.070 |
Why?
|
| Hyperthermia, Induced | 2 | 2005 | 5 | 0.070 |
Why?
|
| Jogging | 1 | 2005 | 3 | 0.070 |
Why?
|
| Medial Collateral Ligament, Knee | 1 | 2006 | 7 | 0.070 |
Why?
|
| Muscular Atrophy | 1 | 2005 | 6 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2019 | 146 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 125 | 0.070 |
Why?
|
| Glucosamine | 1 | 2005 | 9 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2005 | 7 | 0.070 |
Why?
|
| Joints | 1 | 2006 | 97 | 0.070 |
Why?
|
| Sulfur Radioisotopes | 1 | 2005 | 13 | 0.070 |
Why?
|
| Chondroitin Sulfates | 1 | 2005 | 28 | 0.070 |
Why?
|
| Sulfates | 1 | 2005 | 16 | 0.070 |
Why?
|
| Education, Continuing | 1 | 2005 | 14 | 0.070 |
Why?
|
| Fractures, Spontaneous | 1 | 2005 | 11 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2005 | 13 | 0.070 |
Why?
|
| Bone Marrow Diseases | 1 | 2005 | 8 | 0.070 |
Why?
|
| Osteonecrosis | 1 | 2005 | 19 | 0.070 |
Why?
|
| Shoulder Fractures | 1 | 2005 | 26 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2016 | 87 | 0.070 |
Why?
|
| Fracture Fixation | 1 | 2005 | 24 | 0.070 |
Why?
|
| Arthrometry, Articular | 2 | 2017 | 14 | 0.070 |
Why?
|
| Edema | 1 | 2005 | 38 | 0.060 |
Why?
|
| Diet | 1 | 2006 | 174 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2005 | 57 | 0.060 |
Why?
|
| Joint Capsule | 1 | 2005 | 43 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 130 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 223 | 0.060 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 52 | 0.060 |
Why?
|
| Prosthesis Design | 2 | 2019 | 502 | 0.060 |
Why?
|
| Glycosaminoglycans | 2 | 2017 | 51 | 0.060 |
Why?
|
| Surface Properties | 2 | 2009 | 144 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 432 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 437 | 0.060 |
Why?
|
| Ligaments | 1 | 2023 | 15 | 0.060 |
Why?
|
| Radiostereometric Analysis | 1 | 2023 | 7 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 215 | 0.060 |
Why?
|
| Medical Illustration | 2 | 2015 | 20 | 0.060 |
Why?
|
| Obesity | 1 | 2006 | 291 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 1999 | 251 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 28 | 0.060 |
Why?
|
| Skin Temperature | 1 | 2003 | 2 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 2003 | 19 | 0.060 |
Why?
|
| Fascia Lata | 1 | 2023 | 7 | 0.060 |
Why?
|
| Interleukin-1beta | 2 | 2013 | 55 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 68 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2009 | 96 | 0.060 |
Why?
|
| Gene Expression | 2 | 2013 | 226 | 0.050 |
Why?
|
| Indazoles | 1 | 2022 | 2 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2002 | 86 | 0.050 |
Why?
|
| Automation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Pyridines | 1 | 2022 | 42 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 37 | 0.050 |
Why?
|
| Inositol | 1 | 2021 | 7 | 0.050 |
Why?
|
| Rats, Inbred Lew | 2 | 1999 | 11 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 23 | 0.050 |
Why?
|
| Fetus | 1 | 2001 | 56 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 21 | 0.050 |
Why?
|
| Lipids | 1 | 2021 | 36 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 72 | 0.050 |
Why?
|
| Glucose | 1 | 2021 | 59 | 0.050 |
Why?
|
| Chorion | 1 | 2020 | 2 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 39 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 3 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2020 | 5 | 0.050 |
Why?
|
| Computers | 1 | 2021 | 26 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 24 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 188 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 26 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2020 | 10 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2020 | 12 | 0.050 |
Why?
|
| Osteogenesis | 2 | 1999 | 96 | 0.050 |
Why?
|
| Steroids | 1 | 2020 | 22 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2020 | 66 | 0.050 |
Why?
|
| Survival Analysis | 2 | 1998 | 298 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 219 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 47 | 0.050 |
Why?
|
| Sports | 1 | 2020 | 36 | 0.050 |
Why?
|
| Inflammation | 2 | 2012 | 344 | 0.050 |
Why?
|
| Commerce | 1 | 2020 | 13 | 0.050 |
Why?
|
| Proteomics | 1 | 2020 | 91 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2019 | 27 | 0.050 |
Why?
|
| Elastic Modulus | 1 | 2019 | 12 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2019 | 19 | 0.050 |
Why?
|
| Thrombin | 1 | 2019 | 12 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 49 | 0.050 |
Why?
|
| Rehabilitation | 1 | 2019 | 14 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2020 | 70 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2001 | 226 | 0.040 |
Why?
|
| Morphine | 1 | 2020 | 79 | 0.040 |
Why?
|
| Motion Therapy, Continuous Passive | 1 | 2019 | 5 | 0.040 |
Why?
|
| Desiccation | 1 | 2019 | 5 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 20 | 0.040 |
Why?
|
| Immobilization | 1 | 1999 | 14 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 121 | 0.040 |
Why?
|
| Angiography | 1 | 1999 | 38 | 0.040 |
Why?
|
| Ischemia | 1 | 1999 | 27 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 134 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2019 | 67 | 0.040 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1998 | 1 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 81 | 0.040 |
Why?
|
| Nitric Oxide | 2 | 2009 | 101 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1998 | 26 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2019 | 73 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 1998 | 13 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1998 | 24 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2018 | 8 | 0.040 |
Why?
|
| Forms and Records Control | 1 | 1998 | 10 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2018 | 14 | 0.040 |
Why?
|
| Interferon-beta | 1 | 1997 | 7 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1997 | 26 | 0.040 |
Why?
|
| Patient Admission | 1 | 1998 | 27 | 0.040 |
Why?
|
| Michigan | 1 | 2017 | 16 | 0.040 |
Why?
|
| Porosity | 1 | 1997 | 71 | 0.040 |
Why?
|
| Femoral Neck Fractures | 1 | 1997 | 13 | 0.040 |
Why?
|
| Hyaluronan Synthases | 1 | 2017 | 8 | 0.040 |
Why?
|
| Coracoid Process | 1 | 2017 | 6 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1997 | 59 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 1997 | 33 | 0.040 |
Why?
|
| Skin | 1 | 2018 | 117 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 145 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 39 | 0.040 |
Why?
|
| Tarsal Bones | 1 | 2016 | 7 | 0.040 |
Why?
|
| Muscle Fatigue | 1 | 2017 | 10 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 7 | 0.040 |
Why?
|
| Computer-Aided Design | 1 | 2017 | 16 | 0.040 |
Why?
|
| Interleukins | 1 | 2017 | 37 | 0.040 |
Why?
|
| Industry | 1 | 2016 | 9 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 1997 | 364 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 1997 | 87 | 0.040 |
Why?
|
| Titanium | 1 | 1997 | 209 | 0.040 |
Why?
|
| Online Systems | 1 | 2016 | 5 | 0.040 |
Why?
|
| Early Ambulation | 1 | 2016 | 20 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 12 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2016 | 13 | 0.040 |
Why?
|
| Proprioception | 1 | 2016 | 19 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2016 | 36 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 21 | 0.040 |
Why?
|
| Hypertension | 1 | 2018 | 266 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2015 | 3 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 84 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 65 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 15 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 1996 | 54 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 56 | 0.030 |
Why?
|
| Photography | 1 | 2015 | 17 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 46 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 52 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 27 | 0.030 |
Why?
|
| Family | 1 | 1996 | 88 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 47 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2014 | 6 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 13 | 0.030 |
Why?
|
| Occupational Injuries | 1 | 2015 | 8 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 78 | 0.030 |
Why?
|
| Thorax | 1 | 2014 | 12 | 0.030 |
Why?
|
| Immunization | 1 | 1994 | 47 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 33 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2014 | 24 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 55 | 0.030 |
Why?
|
| Denmark | 1 | 2014 | 12 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1996 | 115 | 0.030 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 8 | 0.030 |
Why?
|
| Thigh | 1 | 2014 | 34 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2016 | 138 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 23 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 1998 | 329 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 125 | 0.030 |
Why?
|
| Mesons | 1 | 2014 | 5 | 0.030 |
Why?
|
| Electrons | 1 | 2014 | 19 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 63 | 0.030 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 37 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 18 | 0.030 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2013 | 15 | 0.030 |
Why?
|
| Acellular Dermis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Hip | 1 | 2013 | 40 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2013 | 7 | 0.030 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 145 | 0.030 |
Why?
|
| ADAMTS5 Protein | 1 | 2013 | 27 | 0.030 |
Why?
|
| Metals | 1 | 2014 | 160 | 0.030 |
Why?
|
| Integrins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Analgesics | 1 | 2014 | 108 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Clavicle | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 108 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 106 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2013 | 25 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 254 | 0.030 |
Why?
|
| Metabolism | 1 | 2012 | 9 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 12 | 0.030 |
Why?
|
| Plants | 1 | 2012 | 9 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 15 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 28 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2012 | 17 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 22 | 0.030 |
Why?
|
| Species Specificity | 1 | 2012 | 70 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2013 | 303 | 0.030 |
Why?
|
| Artificial Cells | 1 | 2012 | 1 | 0.030 |
Why?
|
| Proteins | 1 | 2012 | 72 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 65 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2012 | 16 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2012 | 20 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2012 | 64 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2012 | 49 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 264 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2012 | 156 | 0.030 |
Why?
|
| Device Removal | 1 | 2012 | 85 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1991 | 86 | 0.030 |
Why?
|
| Apoptosis | 1 | 2012 | 251 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 213 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 1991 | 76 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 284 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 254 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 117 | 0.020 |
Why?
|
| Occupations | 1 | 2010 | 15 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 91 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 482 | 0.020 |
Why?
|
| Fertility Agents, Female | 1 | 2009 | 1 | 0.020 |
Why?
|
| Hysterosalpingography | 1 | 2009 | 2 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 4 | 0.020 |
Why?
|
| Clomiphene | 1 | 2009 | 5 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 20 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 605 | 0.020 |
Why?
|
| Sheep | 1 | 2008 | 39 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 52 | 0.020 |
Why?
|
| Preservation, Biological | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2008 | 18 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 234 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 46 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2007 | 73 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 55 | 0.020 |
Why?
|
| Cell Movement | 1 | 2006 | 105 | 0.020 |
Why?
|
| Minicomputers | 1 | 2005 | 1 | 0.020 |
Why?
|
| Selection Bias | 1 | 2005 | 10 | 0.020 |
Why?
|
| Thermography | 1 | 2005 | 12 | 0.020 |
Why?
|
| Body Temperature | 1 | 2005 | 58 | 0.020 |
Why?
|
| Immunoassay | 1 | 1984 | 41 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2001 | 78 | 0.010 |
Why?
|
| Polyglycolic Acid | 1 | 1999 | 2 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1999 | 2 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1999 | 8 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1999 | 16 | 0.010 |
Why?
|
| Rhode Island | 1 | 1998 | 1 | 0.010 |
Why?
|
| Axilla | 1 | 1998 | 11 | 0.010 |
Why?
|
| Massachusetts | 1 | 1998 | 19 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 68 | 0.010 |
Why?
|
| Interferon beta-1b | 1 | 1997 | 1 | 0.010 |
Why?
|
| Interferon beta-1a | 1 | 1997 | 2 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1998 | 81 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1998 | 340 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 340 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 3 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1996 | 17 | 0.010 |
Why?
|
| Haplotypes | 1 | 1996 | 61 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1996 | 23 | 0.010 |
Why?
|
| Equipment Reuse | 1 | 1995 | 3 | 0.010 |
Why?
|
| Hospitals, Special | 1 | 1995 | 6 | 0.010 |
Why?
|
| Cost Control | 1 | 1995 | 11 | 0.010 |
Why?
|
| New York City | 1 | 1995 | 18 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1994 | 20 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1994 | 28 | 0.010 |
Why?
|
| Program Development | 1 | 1995 | 69 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1994 | 110 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 29 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1984 | 19 | 0.000 |
Why?
|
| Laboratories | 1 | 1984 | 25 | 0.000 |
Why?
|
| Quality Control | 1 | 1984 | 43 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1984 | 28 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 25 | 0.000 |
Why?
|